News
新聞與媒體
【Significant Favorable?News】Poly Pharmaceuticals contributes to the significant achievements of CDMO's innovative immunotherapy drugs, taking a step closer to full commercialization !
Remarkable results achieved on Innovative Immunotherapy Drugs Strengthen the cooperation between Pol...
View details
Hainan Poly Pharm.Co., Ltd in the 2024 DCAT Week
Hainan Poly Pharm.Co., Ltd will be participating in the 2024 DCAT Week (Drug, Chemical & Associa...
View details
【?INVITATION】CPHI2023 Booth No. : 2P29 --POLY PHARM
CPHI2023 will be held in 24th~26th Oct. 2023 in Barcelona, SpainHainan Poly Pharm Co.,Lted will ...
View details
Zhejiang Poly Pharmaceutical's Eye Drop Workshop Complies with Chinese, American, and European GMP Requirements - Open to Domestic and International CDMO/CMO Collaborations
Zhejiang Poly Pharmaceutical is a wholly-owned subsidiary of Hainan Poly Pharmaceutical (stock code:...
View details
Anhui Poly Pharmaceutical's Magnesium Hydroxide API Approved for Market, with a Yearly Production Capacity of Up to 200 Tons!
Anhui Poly Pharmaceutical Co., Ltd. (hereinafter referred to as "Anhui Poly") recently rec...
View details
Poly Pharmaceutical Obtains Market Approval for Azithromycin Injection in Israel, Further Securing Antibiotic Supply
Poly Pharmaceutical Co., Ltd. (hereinafter referred to as "Poly Pharmaceutical") recently ...
View details
Hainan Poly Pharmaceuticals’ Injection and Raw Material Workshops Receive US FDA Certification Again!
From June 22, 2023, to June 30, 2023, Poly Pharmaceuticals underwent an on-site inspection by the Un...
View details
Poly Pharmaceuticals’ High-End Pediatric Medicine Open the US Market, Zhejiang Poly's Azithromycin Dry Powder Suspension (Precision Dosing) Becomes the First Chinese Product to Receive FDA Approval!
In the United States, stringent requirements for precision dosing of pediatric medications are in pl...
View details
Home